文献速递青光眼

注册青光眼试验的发表率与发表模式

Publication Rates and Patterns of Registered Glaucoma Trials.
PubMed 文献 · Ophthalmology · 2025-04-10

该横断面分析检索了ClinicalTrials.gov上全部注册青光眼试验,发现969项试验中仅510项(53%)发表,222项(23%)在FDA规定的12至24个月报告期内发表,312项(32%)在ClinicalTrials.gov有结果可用。从研究开始到主要完成平均24个月,从主要完成到发表再延迟34个月。

要点

  • 969项注册青光眼试验中仅510项(53%)发表,222项(23%)在FDA规定的12至24个月报告期内发表。
  • 从研究开始到主要完成平均24个月,从主要完成到发表再延迟34个月。
  • 非美国研究较美国研究、非企业赞助较企业赞助更可能发表(均P < 0.05)。

核心结论

  • 注册青光眼试验中仅约一半发表,不足25%遵守FDA规定的1至2年报告期,从主要完成到发表总体显著延迟近3年,提示青光眼试验信息传播可能存在偏倚。

研究设计与样本

  • 横断面分析,研究对象为ClinicalTrials.gov上全部注册青光眼试验,于2024年8月检索,共识别969项试验。

主要发现

  • 969项试验中510项(53%)发表,222项(23%)在FDA规定的12至24个月报告期内发表,312项(32%)在ClinicalTrials.gov有结果可用。
  • 575项(59%)为非手术试验,748项(77%)为干预性试验,518项(54%)为国际试验,512项(53%)为企业赞助。
  • 从研究开始到主要完成平均24个月,从主要完成到发表再延迟34个月。
  • 企业赞助试验较非企业赞助更可能为干预性(88% vs. 65%,P < 0.01)、为药物而非手术(71% vs. 46%,P < 0.01)、基于美国(58% vs. 34%,P < 0.01)、在ClinicalTrials.gov有结果可用(45% vs. 18%,P < 0.01)、完成更快(22 vs. 32个月,P < 0.01)。
  • 企业赞助和非企业赞助试验中,干预性试验均较观察性试验更可能发表(P = 0.04,P = 0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the publication rates and patterns of registered glaucoma trials. DESIGN: Cross-sectional analysis. PARTICIPANTS: All registered glaucoma trials from ClinicalTrials.gov. METHODS: The National Institutes of Health ClinicalTrials.gov was queried in August 2024 for all registered glaucoma trials. Study characteristics and time from study start date to primary completion date were extracted, and verification of publication in peer-reviewed journals was confirmed using PubMed.gov, ClinicalTrials.gov, and Google Scholar. MAIN OUTCOME MEASURES: Publication status and characteristics associated with publication. RESULTS: A total of 969 trials were identified, of which 510 (53%) were published, 222 (23%) were published within the mandated reporting period of 12 to 24 months by the Food and Drug Administration (FDA), and 312 (32%) had results available on ClinicalTrials.gov. Of the evaluated trials, 575 (59%) were nonsurgical (did not focus on surgical procedures), 748 were interventional (77%), 518 were international (54%), and 512 were industry sponsored (53%). The average time from study start date to primary completion date was 24 months, with a delay of primary completion date to publication date of another 34 months. In the overall cohort, non-US-based compared with US-based studies and nonindustry compared with industry sponsorships were more likely to be published (P < 0.05 for both). Industry-sponsored trials were more likely to be interventional (investigator assigned participants to an intervention or no intervention) than observational (participants may receive interventions as part of a study group but not specifically assigned by investigators) (88% vs. 65%, P < 0.01), to be medical rather than surgical (71% vs. 46%, P < 0.01), to be based in the United States (58% vs. 34%, P < 0.01), to have results available on ClinicalTrials.gov (45% vs. 18%, P < 0.01), and to be completed sooner (22 vs. 32 months, P < 0.01). For both industry- and nonindustry-sponsored trials, interventional trials were more likely to be published compared with observational trials (P = 0.04, P = 0.02, respectively). CONCLUSIONS: Only about half of all registered glaucoma trials from ClinicalTrials.gov were published, with less than 25% complying with the mandated FDA report period of 1 to 2 years and overall, a significant delay of nearly 3 years from study primary completion date to publication date. This suggests potential bias in information dissemination of glaucoma trials. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Meller LLT, Kashaf MS, Sambo A, et al. Publication Rates and Patterns of Registered Glaucoma Trials. Ophthalmology. 2025. PMID: 40216202. doi:10.1016/j.ophtha.2025.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。